Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening

著者: Grant L. Lin, Kelli M. Wilson, Michele Ceribelli, Benjamin Z. Stanton, Pamelyn J. Woo, Sara Kreimer, Elizabeth Y. Qin, Xiaohu Zhang, James Lennon, Surya Nagaraja, Patrick J. Morris, Michael A. Quezada, Shawn Gillespie, Damien Duveau, Aleksandra M. Michalowski, Paul Shinn, Rajarshi Guha, Marc Ferrer, Carleen Klumpp‐Thomas, Sam Michael, Crystal McKnight, Paras S. Minhas, Zina Itkin, Eric H. Raabe, Lu Chen, Reem Ghanem, Anna C. Geraghty, Lijun Ni, Katrin I. Andreasson, Nicholas A. Vitanza, Katherine E. Warren, Craig J. Thomas, Michelle Monje - Science Translational Medicine 2019 被引用: 258

) production via nicotinamide phosphoribosyltransferase (NAMPT) inhibition demonstrated that metabolic catastrophe drives the combination-induced cytotoxicity. This study provides a comprehensive single-agent and combinatorial drug screen for DMG and identifies concomitant HDAC and proteasome inhibition as a promising therapeutic strategy that underscores underrecognized metabolic vulnerabilities in DMG.